Glenmark Licenses Cancer Drug Envafolimab for Asia & More
By Rediff Money Desk, NEWDELHI Jan 25, 2024 10:54
Glenmark Pharmaceuticals has secured licensing rights for Envafolimab, a cancer drug, in India, Asia Pacific, and other regions. The drug, developed by Jiangsu Alphamab and 3D Medicines, is a PD-L1 inhibitor.
New Delhi, Jan 25 (PTI) Glenmark Pharmaceuticals Ltd on Thursday said its arm Glenmark Specialty S A (GSSA) has signed a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), used in cancer treatment.
Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.
Glenmark will be responsible for further developing, registering, and commercialising Envafolimab in these regions.
On behalf of the licensors, Jiangsu Alphamab will receive a low double-digit million US dollar amount up to launch, additional triple-digit million US dollar milestone payments based on sales performance across the length of the agreement, and a royalty fee of single to double digits depending on the level of net sales, the statement said.
Jiangsu Alphamab will be responsible for the manufacturing of KN035 and will be the exclusive supplier of the product, it added.
"This is an important milestone for Glenmark, as through this transformational deal, we gain access to the first recombinant humanised single domain antibody against PD-L1 in a Sub-Q formulation for a wide territory globally," Glenmark Pharmaceuticals Chairman & Managing Glenn Saldanha said.
Further, he said,"We are excited at the opportunity to take this innovative immuno-oncology product to cancer patients across the emerging markets and meaningfully contribute towards improving their access to potentially life-saving treatments."
Envafolimab, under the brand name ENWEIDA was approved in China by the National Medical Products Administration (Chinese NMPA) in November 2021 for the treatment of adult patients with certain types of advanced solid tumour. It has also been officially included in the "List of Breakthrough Therapies" by the NMPA, the statement said.
Further, Envafolimab is currently being developed in the USA by Tracon Pharma in a pivotal trial in soft tissue sarcoma (STS) subtypes.
The drug has obtained two orphan drug designation from the USFDA (US Food and Drug Administration) for advanced biliary tract cancer and soft tissue sarcoma (STS) and a fast track designation for STS.
Additional indications such as Biliary Tract cancer and non-small cell lung cancer are currently in development, it added.
Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.
Glenmark will be responsible for further developing, registering, and commercialising Envafolimab in these regions.
On behalf of the licensors, Jiangsu Alphamab will receive a low double-digit million US dollar amount up to launch, additional triple-digit million US dollar milestone payments based on sales performance across the length of the agreement, and a royalty fee of single to double digits depending on the level of net sales, the statement said.
Jiangsu Alphamab will be responsible for the manufacturing of KN035 and will be the exclusive supplier of the product, it added.
"This is an important milestone for Glenmark, as through this transformational deal, we gain access to the first recombinant humanised single domain antibody against PD-L1 in a Sub-Q formulation for a wide territory globally," Glenmark Pharmaceuticals Chairman & Managing Glenn Saldanha said.
Further, he said,"We are excited at the opportunity to take this innovative immuno-oncology product to cancer patients across the emerging markets and meaningfully contribute towards improving their access to potentially life-saving treatments."
Envafolimab, under the brand name ENWEIDA was approved in China by the National Medical Products Administration (Chinese NMPA) in November 2021 for the treatment of adult patients with certain types of advanced solid tumour. It has also been officially included in the "List of Breakthrough Therapies" by the NMPA, the statement said.
Further, Envafolimab is currently being developed in the USA by Tracon Pharma in a pivotal trial in soft tissue sarcoma (STS) subtypes.
The drug has obtained two orphan drug designation from the USFDA (US Food and Drug Administration) for advanced biliary tract cancer and soft tissue sarcoma (STS) and a fast track designation for STS.
Additional indications such as Biliary Tract cancer and non-small cell lung cancer are currently in development, it added.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.17 ( -6.43)
- 158804255
- G V Films
- 0.92 ( -2.13)
- 92620172
- Srestha Finvest
- 0.93 (+ 4.49)
- 40021818
- GTL Infrastructure
- 2.21 ( -4.74)
- 33334323
- Spicejet Ltd.
- 57.56 ( -8.33)
- 31426149
MORE NEWS
Augustinus Bader Skincare & Haircare Launches...
Tira brings Augustinus Bader's luxury skincare and haircare to India, offering...
Muthoot Finance Gold Loans Now Available on...
Muthoot Finance announces that its flagship gold loans can now be availed using Google...
NCERT Books Now Available on Amazon India
NCERT textbooks for students from Kindergarten to Class 12 and UPSC aspirants are now...